Biotech | January 24, 2022
USFDA approves IND application for Allied’s cancer treatment
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma
Investment in single-use endoscopes, digital solutions, and endoluminal therapies expected
It is used for the treatment of advanced colorectal and gastric cancer
Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan
The medicine is now approved for eight indications across five different types of cancer in China.
The clinical trial will evaluate the safety, tolerability and pharmacokinetic properties of ICP-723 in patients with solid tumours, and evaluate the anti-tumour efficacy of ICP-723 on NTRK fusion-positive cancers
The product can be used by any lab that conducts NGS testing, making precision medicine accessible to all cancer patients
The drug is approved for the treatment in metastatic colorectal carcinoma, metastatic breast cancer and ovarian, cervical and renal cancer
Subscribe To Our Newsletter & Stay Updated
